Jones Financial Companies’s AbCellera Biologics ABCL Stock Holding History

Jones Financial Companies’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.28K	Sell	1,257 -250	-17%	-$1.22K	﹤0.01%	3826
2026 Q1	$4.93K	Buy	1,507 +842	+127%	+$3.03K	﹤0.01%	3848
2025 Q4	$2.27K	Sell	665 -35	-5%	-$156	﹤0.01%	3787
2025 Q3	$3.32K	Hold	700	–	–	﹤0.01%	3524
2025 Q2	$2.53K	Buy	700 +500	+250%	+$1.25K	﹤0.01%	3388
2025 Q1	$462	Sell	200 -425	-68%	-$1.22K	﹤0.01%	3518
2024 Q4	$1.83K	Sell	625 -300	-32%	-$835	﹤0.01%	3025
2024 Q3	$2.41K	Sell	925 -2,356	-72%	-$6.53K	﹤0.01%	2635
2024 Q2	$9.71K	Hold	3,281	–	–	﹤0.01%	1766
2024 Q1	$14.9K	Buy	+3,281	New	+$16.7K	﹤0.01%	975

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Jones Financial Companies's ABCL Position: Q2 2026 in Review

Jones Financial Companies reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $1.22K and leaving 1,257 shares worth $9.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3826.

Jones Financial Companies first reported a position in ABCL in Q1 2024 and has held it in 10 quarters since. The position peaked at $14.9K in Q1 2024. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Jones Financial Companies held 1,257 shares of AbCellera Biologics worth $9.28K as of Q2 2026.
Jones Financial Companies sold 250 AbCellera Biologics shares in Q2 2026, an estimated $1.22K.
AbCellera Biologics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3826 holding.
Jones Financial Companies first reported a position in AbCellera Biologics in Q1 2024 and has held it in 10 quarters since.
Jones Financial Companies's AbCellera Biologics position peaked at $14.9K in Q1 2024.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.